Working… Menu

Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection (VGX-6150-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02027116
Recruitment Status : Completed
First Posted : January 3, 2014
Last Update Posted : August 7, 2017
Inovio Pharmaceuticals
Information provided by (Responsible Party):
GeneOne Life Science, Inc.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 2015
Actual Study Completion Date : July 2017